Catalposide is a natural agonistic ligand of peroxisome proliferator-activated receptor-α

Biochemical and Biophysical Research Communications

Volumn 422, Issue 4, 2012, Pages 568-572

  Lee, Ji Hae ^a   Jun, Hee jin ^a   Hoang, Minh Hien ^a   Jia, Yaoyao ^a   Han, Xiang Hua ^c   Lee, Dong Ho ^a   Lee, Hak Ju ^b   Hwang, Bang Yeon ^c   Lee, Sung Joon ^a  

^a Korea University   (South Korea)

^b Korea Food Research Institute   (South Korea)

^c Chungbuk National University   (South Korea)

Author keywords

Catalposide; Hepatocyte; Lipid metabolism; Peroxisome proliferator receptor

Indexed keywords

CATALPOSIDE; FATTY ACID TRANSPORTER 4; HIGH DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; ENERGY TRANSFER; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY ACID TRANSPORT; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION; GENE REPRESSION; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LIVER CELL CULTURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPORTER GENE; SEAWEED; UPREGULATION;

FATTY ACIDS; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENES, REPORTER; GLUCOSIDES; HEP G2 CELLS; HEPATOCYTES; HUMANS; HYPERTRIGLYCERIDEMIA; LIGANDS; LIPID METABOLISM; LIPIDS; PPAR ALPHA;

EID: 84862286884     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.05.025     Document Type: Article

References (30)

1. Austin M.A., Hokanson J.E., Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am. J. Cardiol. 1998, 81:7B-12B.
2. Grundy S.M. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am. J. Cardiol. 1999, 83:25f-29f.
3. Grundy S.M. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am. J. Cardiol. 1998, 81:18B-25B.
4. McBride P.E. Triglycerides and risk for coronary heart disease. JAMA 2007, 298:336-338.
5. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
6. Talayero B.G., Sacks F.M. The role of triglycerides in atherosclerosis. Curr. Cardiol. Rep. 2011, 13:544-552.
7. Chinetti G., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 2000, 49:497-505.
8. Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996, 137:354-366.
9. Kersten S., Desvergne B., Wahli W. Roles of PPARs in health and disease. Nature 2000, 405:421-424.
10. Nohara A., Kobayashi J., Mabuchi H. Retinoid X receptor heterodimer variants and cardiovascular risk factors. J. Atheroscler. Thromb. 2009, 16:303-318.
11. Shah A., Rader D.J., Millar J.S. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 2010, 210:35-40.
12. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.G. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98:2088-2093.
13. Chan S.Y., Mancini G.B., Ignaszewski A., Frohlich J. Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study. BMC Clin. Pharmacol. 2008, 8:10.
14. Verges B. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD. Curr. Opin. Lipidol. 2006, 17:653-658.
15. Auwerx J., Schoonjans K., Fruchart J.C., Staels B. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis 1996, 124(Suppl):S29-S37.
16. Ginsberg H.N. Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives. Am. J. Med. 1987, 83:66-70.
17. Ho Y.K., Brown M.S., Goldstein J.L. Hydrolysis and excretion of cytoplasmic cholesteryl esters by macrophages: stimulation by high density lipoprotein and other agents. J. Lipid. Res. 1980, 21:391-398.
18. An S.J., Pae H.O., Oh G.S., Choi B.M., Jeong S., Jang S.I., Oh H., Kwon T.O., Song C.E., Chung H.T. Inhibition of TNF-alpha, IL-1beta, and IL-6 productions and NF-kappa B activation in lipopolysaccharide-activated RAW 264.7 macrophages by catalposide, an iridoid glycoside isolated from Catalpa ovata G. Don (Bignoniaceae). Int. Immunopharmacol. 2002, 2:1173-1181.
19. Oh H., Pae H.O., Oh G.S., Lee S.Y., Chai K.Y., Song C.E., Kwon T.O., Chung H.T., Lee H.S. Inhibition of inducible nitric oxide synthesis by catalposide from Catalpa ovata. Planta Med. 2002, 68:685-689.
20. Cho S.Y., Jun H.J., Lee J.H., Jia Y., Kim K.H., Lee S.J. Linalool reduces the expression of 3-hydroxy-3-methylglutaryl CoA reductase via sterol regulatory element binding protein-2-and ubiquitin-dependent mechanisms. FEBS Lett. 2011, 585:3289-3296.
21. Jia Y., Bhuiyan M.J., Jun H.J., Lee J.H., Hoang M.H., Lee H.J., Kim N., Lee D., Hwang K.Y., Hwang B.Y., Choi D.W., Lee S.J. Ursolic acid is a PPAR-alpha agonist that regulates hepatic lipid metabolism. Bioorg. Med. Chem. Lett. 2011, 21:5876-5880.
22. Jun H.J., Lee J.H., Jia Y., Hoang M.H., Byun H., Kim K.H., Lee S.J. Melissa officinalis essential oil reduces plasma triglycerides in human apolipoprotein e2 transgenic mice by inhibiting sterol regulatory element-binding protein-1c-dependent fatty acid synthesis. J. Nutr. 2012, 142:432-440.
23. Lee J.H., Jun H.J., Jia Y., Kim W., Choi S.G., Lee S.J. Critical role of peroxisome proliferator activated receptor-delta on body fat reduction in C57BL/6J and human apolipoprotein E2 transgenic mice fed delipidated soybean. J. Agric. Food. Chem. 2011, 59:11872-11881.
24. Kwak J.H., Kim H.J., Lee K.H., Kang S.C., Zee O.P. Antioxidative iridoid glycosides and phenolic compounds from Veronica peregrina. Arch. Pharm. Res. 2009, 32:207-213.
25. Goldberg I.J. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J. Lipid. Res. 1996, 37:693-707.
26. Man W.C., Miyazaki M., Chu K., Ntambi J. Colocalization of SCD1 and DGAT2: implying preference for endogenous monounsaturated fatty acids in triglyceride synthesis. J. Lipid. Res. 2006, 47:1928-1939.
27. Mead J.R., Irvine S.A., Ramji D.P. Lipoprotein lipase: structure, function, regulation, and role in disease. J. Mol. Med. 2002, 80:753-769.
28. Hunt M.C., Nousiainen S.E., Huttunen M.K., Orii K.E., Svensson L.T., Alexson S.E. Peroxisome proliferator-induced long chain acyl-CoA thioesterases comprise a highly conserved novel multi-gene family involved in lipid metabolism. J. Biol. Chem. 1999, 274:34317-34326.
29. Saleh M.C., Wheeler M.B., Chan C.B. Uncoupling protein-2: evidence for its function as a metabolic regulator. Diabetologia 2003, 46:133-134.
30. Attie A.D., Kastelein J.P., Hayden M.R. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J. Lipid. Res. 2001, 42:1717-1726.